Evidence-Based Evaluation on Off-label Use of Paclitaxel(Albumin Bound)Against Gynecologic Cancer
LI Yuanwen
ZHANG Shuang
ZHAO Dan
LIU Jun
SUN Nan
REN Yanli
GUO Hua
Abstract：Objective To evaluate the rationality of off-label use of paclitaxel(albumin bound)in the treatment of cervical cancer,endometrial carcinoma and ovarian cancer.Methods The latest edition of domestic and foreign drug labels,Micromedex datebase and authoritative guidelines were retrieved;PubMed,Embase,Cochrane Library,CNKI,VIP,and Wanfang databases were systematically searched.Evidence-based medicine grade evaluation was conducted after quality evaluation.Results Paclitaxel(albumin bound)for treatment of recurrent or metastatic cervical cancer and recurrent ovarian cancer,its effectiveness level was class Ⅱa,recommendation level was class Ⅱb,and evidence level was class B.For treatment of recurrent ovarian cancer,its effectiveness level was class Ⅱa,recommendation level was class Ⅱb,and evidence level was class C.Conclusion At present,there is only low level evidence for paclitaxel(albumin bound)against gynecologic cancer.Therefore,high-quality clinical studies are needed to demonstrate its safety and efficacy.
Keywords：uteurine cervical neoplasmsendometrial neoplasmsovarian neoplasmspaclitaxel(albumin bound)off-label usevidence-based evaluation
Publication Date：2025-04-28
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：5( 1371-1375 )